Skip to main content

Advertisement

SpringerLink
Log in

Clinical trial data and emerging strategies: HER2-positive breast cancer

  • Review
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

A deeper insight into tumor biology and HER2 signaling has led to the development of novel anti-HER2 drugs that have significantly improved the prognosis of patients with HER2-positive breast cancer. The breast cancer immune microenvironment has emerged as a potential prognostic factor. Moreover, the host immune system not only seems to play a critical role in the prognosis of HER2-positive breast cancer, but also seems to modulate treatment response to some HER2-targeted agents. Here, we review the latest evidence of the role of immunotherapy in HER2-positive breast cancer and present emerging strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Data availability

Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

References

  1. Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E, Clark E, Knott A, Restuccia E, Benyunes MC, Cortes J, group Cs (2020) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol 21(4):519–530. https://doi.org/10.1016/S1470-2045(19)30863-0

    Article  Google Scholar 

  2. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13(1):25–32. https://doi.org/10.1016/S1470-2045(11)70336-9

    Article  CAS  PubMed  Google Scholar 

  3. Piccart M, Procter M, Fumagalli D, de Azambuja E, Clark E, Ewer MS, Restuccia E, Jerusalem G, Dent S, Reaby L, Bonnefoi H, Krop I, Liu TW, Pienkowski T, Toi M, Wilcken N, Andersson M, Im YH, Tseng LM, Lueck HJ, Colleoni M, Monturus E, Sicoe M, Guillaume S, Bines J, Gelber RD, Viale G, Thomssen C, Committee AS, Investigators (2021) Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6 years’ follow-up. J Clin Oncol. https://doi.org/10.1200/JCO.20.01204

    Article  Google Scholar 

  4. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Dieras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K, Group ES (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367(19):1783–1791. https://doi.org/10.1056/NEJMoa1209124

    Article  CAS  Google Scholar 

  5. von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wulfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr, Investigators K (2019) Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 380(7):617–628. https://doi.org/10.1056/NEJMoa1814017

    Article  Google Scholar 

  6. Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im SA, Lee KS, Hurvitz SA, Cortes J, Lee C, Chen S, Zhang L, Shahidi J, Yver A, Krop I, Investigators DE-B (2020) Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med 382(7):610–621. https://doi.org/10.1056/NEJMoa1914510

    Article  CAS  PubMed  Google Scholar 

  7. Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, Lin NU, Borges V, Abramson V, Anders C, Bedard PL, Oliveira M, Jakobsen E, Bachelot T, Shachar SS, Muller V, Braga S, Duhoux FP, Greil R, Cameron D, Carey LA, Curigliano G, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pegram M, Slamon D, Palanca-Wessels MC, Walker L, Feng W, Winer EP (2020) Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med 382(7):597–609. https://doi.org/10.1056/NEJMoa1914609

    Article  CAS  PubMed  Google Scholar 

  8. Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomasevic Z, Denduluri N, Separovic R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A, Exte NETSG (2017) Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 18(12):1688–1700. https://doi.org/10.1016/S1470-2045(17)30717-9

    Article  CAS  PubMed  Google Scholar 

  9. Saura C, Oliveira M, Feng YH, Dai MS, Chen SW, Hurvitz SA, Kim SB, Moy B, Delaloge S, Gradishar W, Masuda N, Palacova M, Trudeau ME, Mattson J, Yap YS, Hou MF, De Laurentiis M, Yeh YM, Chang HT, Yau T, Wildiers H, Haley B, Fagnani D, Lu YS, Crown J, Lin J, Takahashi M, Takano T, Yamaguchi M, Fujii T, Yao B, Bebchuk J, Keyvanjah K, Bryce R, Brufsky A, Investigators N (2020) Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with >/= 2 HER2-directed regimens: phase III NALA trial. J Clin Oncol 38(27):3138–3149. https://doi.org/10.1200/JCO.20.00147

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Pernas S, Tolaney SM (2020) Targeting HER2 heterogeneity in early-stage breast cancer. Curr Opin Oncol 32(6):545–554. https://doi.org/10.1097/CCO.0000000000000685

    Article  CAS  PubMed  Google Scholar 

  11. Dieci MV, Miglietta F, Guarneri V (2021) Immune infiltrates in breast cancer: recent updates and clinical implications. Cells. https://doi.org/10.3390/cells10020223

    Article  PubMed  PubMed Central  Google Scholar 

  12. Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, Budczies J, Huober J, Klauschen F, Furlanetto J, Schmitt WD, Blohmer JU, Karn T, Pfitzner BM, Kummel S, Engels K, Schneeweiss A, Hartmann A, Noske A, Fasching PA, Jackisch C, van Mackelenbergh M, Sinn P, Schem C, Hanusch C, Untch M, Loibl S (2018) Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 19(1):40–50. https://doi.org/10.1016/S1470-2045(17)30904-X

    Article  PubMed  Google Scholar 

  13. Nuciforo P, Pascual T, Cortes J, Llombart-Cussac A, Fasani R, Pare L, Oliveira M, Galvan P, Martinez N, Bermejo B, Vidal M, Pernas S, Lopez R, Munoz M, Garau I, Manso L, Alarcon J, Martinez E, Rodrik-Outmezguine V, Brase JC, Villagrasa P, Prat A, Holgado E (2018) A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade. Ann Oncol 29(1):170–177. https://doi.org/10.1093/annonc/mdx647

    Article  CAS  PubMed  Google Scholar 

  14. Griguolo G, Pascual T, Dieci MV, Guarneri V, Prat A (2019) Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer. J Immunother Cancer 7(1):90. https://doi.org/10.1186/s40425-019-0548-6

    Article  PubMed  PubMed Central  Google Scholar 

  15. Harris SJ, Brown J, Lopez J, Yap TA (2016) Immuno-oncology combinations: raising the tail of the survival curve. Cancer Biol Med 13(2):171–193. https://doi.org/10.20892/j.issn.2095-3941.2016.0015

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X, Sattar H, Wang Y, Brown NK, Greene M, Liu Y, Tang J, Wang S, Fu YX (2010) The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 18(2):160–170. https://doi.org/10.1016/j.ccr.2010.06.014

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Di Modica M, Sfondrini L, Regondi V, Varchetta S, Oliviero B, Mariani G, Bianchi GV, Generali D, Balsari A, Triulzi T, Tagliabue E (2016) Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition. Oncotarget 7(1):255–265. https://doi.org/10.18632/oncotarget.6353

    Article  PubMed  Google Scholar 

  18. Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden G, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O’Toole S, Larsimont D, de Wind R, Curigliano G, Andre F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB (2017) Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immunooncology Biomarkers Working Group: part 1: assessing the host immune response, TILs in invasive breast carcinoma and ductal carcinoma in situ, metastatic tumor deposits and areas for further research. Adv Anat Pathol 24(5):235–251. https://doi.org/10.1097/PAP.0000000000000162

    Article  PubMed  PubMed Central  Google Scholar 

  19. Glajcar A, Szpor J, Hodorowicz-Zaniewska D, Tyrak KE, Okon K (2019) The composition of T cell infiltrates varies in primary invasive breast cancer of different molecular subtypes as well as according to tumor size and nodal status. Virchows Arch 475(1):13–23. https://doi.org/10.1007/s00428-019-02568-y

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Dieci MV, Tsvetkova V, Orvieto E, Piacentini F, Ficarra G, Griguolo G, Miglietta F, Giarratano T, Omarini C, Bonaguro S, Cappellesso R, Aliberti C, Vernaci G, Giorgi CA, Faggioni G, Tasca G, Conte P, Guarneri V (2018) Immune characterization of breast cancer metastases: prognostic implications. Breast Cancer Res 20(1):62. https://doi.org/10.1186/s13058-018-1003-1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Mokrab Y, Newman AM, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Pedamallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CS, Cancer Genome Atlas Research N, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich I (2018) The immune landscape of cancer. Immunity 48(4):812–830 e814. https://doi.org/10.1016/j.immuni.2018.03.023

  22. Kumagai S, Koyama S, Nishikawa H (2021) Antitumour immunity regulated by aberrant ERBB family signalling. Nat Rev Cancer 21(3):181–197. https://doi.org/10.1038/s41568-020-00322-0

    Article  CAS  PubMed  Google Scholar 

  23. Guarneri V, Dieci MV, Bisagni G, Brandes AA, Frassoldati A, Cavanna L, Musolino A, Giotta F, Rimanti A, Garrone O, Bertone E, Cagossi K, Nanni O, Piacentini F, Orvieto E, Griguolo G, Curtarello M, Urso L, Pare L, Chic N, D’Amico R, Prat A, Conte P (2020) PIK3CA mutation in the ShortHER randomized adjuvant trial for patients with early HER2(+) breast cancer: association with prognosis and integration with PAM50 subtype. Clin Cancer Res 26(22):5843–5851. https://doi.org/10.1158/1078-0432.CCR-20-1731

    Article  CAS  PubMed  Google Scholar 

  24. Carey LA, Berry DA, Cirrincione CT, Barry WT, Pitcher BN, Harris LN, Ollila DW, Krop IE, Henry NL, Weckstein DJ, Anders CK, Singh B, Hoadley KA, Iglesia M, Cheang MC, Perou CM, Winer EP, Hudis CA (2016) Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus trastuzumab with or without lapatinib. J Clin Oncol 34(6):542–549. https://doi.org/10.1200/JCO.2015.62.1268

    Article  CAS  PubMed  Google Scholar 

  25. Fumagalli D, Venet D, Ignatiadis M, Azim HA Jr, Maetens M, Rothe F, Salgado R, Bradbury I, Pusztai L, Harbeck N, Gomez H, Chang TW, Coccia-Portugal MA, Di Cosimo S, de Azambuja E, de la Pena L, Nuciforo P, Brase JC, Huober J, Baselga J, Piccart M, Loi S, Sotiriou C (2016) RNA sequencing to predict response to neoadjuvant anti-HER2 therapy: a secondary analysis of the NeoALTTO randomized clinical trial. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2016.3824

    Article  Google Scholar 

  26. Solinas C, Carbognin L, De Silva P, Criscitiello C, Lambertini M (2017) Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: current state of the art. Breast 35:142–150. https://doi.org/10.1016/j.breast.2017.07.005

    Article  PubMed  Google Scholar 

  27. Ignatiadis M, Van den Eynden G, Roberto S, Fornili M, Bareche Y, Desmedt C, Rothe F, Maetens M, Venet D, Holgado E, McNally V, Kiermaier A, Savage HM, Wilson TR, Cortes J, Schneeweiss A, Willard-Gallo K, Biganzoli E, Sotiriou C (2019) Tumor-infiltrating lymphocytes in patients receiving trastuzumab/pertuzumab-based chemotherapy: a TRYPHAENA substudy. J Natl Cancer Inst 111(1):69–77. https://doi.org/10.1093/jnci/djy076

    Article  CAS  PubMed  Google Scholar 

  28. Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Desmedt C, Piccart MJ, Loibl S, Denkert C, Smyth MJ, Joensuu H, Sotiriou C (2014) Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 25(8):1544–1550. https://doi.org/10.1093/annonc/mdu112

    Article  CAS  PubMed  Google Scholar 

  29. Perez EA, Ballman KV, Tenner KS, Thompson EA, Badve SS, Bailey H, Baehner FL (2016) Association of stromal tumor-infiltrating lymphocytes with recurrence-free survival in the N9831 adjuvant trial in patients with early-stage HER2-positive breast cancer. JAMA Oncol 2(1):56–64. https://doi.org/10.1001/jamaoncol.2015.3239

    Article  PubMed  PubMed Central  Google Scholar 

  30. Kim RS, Song N, Gavin PG, Salgado R, Bandos H, Kos Z, Floris G, Eynden G, Badve S, Demaria S, Rastogi P, Fehrenbacher L, Mamounas EP, Swain SM, Wickerham DL, Costantino JP, Paik S, Wolmark N, Geyer CE, Lucas PC, Pogue-Geile KL (2019) Stromal tumor-infiltrating lymphocytes in NRG oncology/NSABP B-31 adjuvant trial for early-stage HER2-positive breast cancer. J Natl Cancer Inst 111(8):867–871. https://doi.org/10.1093/jnci/djz032

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Dieci MV, Conte P, Bisagni G, Brandes AA, Frassoldati A, Cavanna L, Musolino A, Giotta F, Rimanti A, Garrone O, Bertone E, Cagossi K, Sarti S, Ferro A, Piacentini F, Maiorana A, Orvieto E, Sanders M, Miglietta F, Balduzzi S, D’Amico R, Guarneri V (2019) Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. Ann Oncol 30(3):418–423. https://doi.org/10.1093/annonc/mdz007

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Prat A, Guarneri V, Pare L, Griguolo G, Pascual T, Dieci MV, Chic N, Gonzalez-Farre B, Frassoldati A, Sanfeliu E, Cejalvo JM, Munoz M, Bisagni G, Braso-Maristany F, Urso L, Vidal M, Brandes AA, Adamo B, Musolino A, Miglietta F, Conte B, Oliveira M, Saura C, Pernas S, Alarcon J, Llombart-Cussac A, Cortes J, Manso L, Lopez R, Ciruelos E, Schettini F, Villagrasa P, Carey LA, Perou CM, Piacentini F, D’Amico R, Tagliafico E, Parker JS, Conte P (2020) A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. Lancet Oncol 21(11):1455–1464. https://doi.org/10.1016/S1470-2045(20)30450-2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Krop IE, Paulson J, Campbell C, Kiermaier AC, Andre F, Fumagalli D, de Haas S, Salgado R, Denkert C, Loibl S, Bailey A, Phillips GL, Frank E, Piccart M, Viale G, Loi S (2019) Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC): biomarker analysis of the APHINITY trial [abstract]. J Clin Oncol 37(15_suppl):1012

  34. Llombart-Cussac A, Cortes J, Pare L, Galvan P, Bermejo B, Martinez N, Vidal M, Pernas S, Lopez R, Munoz M, Nuciforo P, Morales S, Oliveira M, de la Pena L, Pelaez A, Prat A (2017) HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. Lancet Oncol 18(4):545–554. https://doi.org/10.1016/S1470-2045(17)30021-9

    Article  CAS  PubMed  Google Scholar 

  35. Hamy AS, Pierga JY, Sabaila A, Laas E, Bonsang-Kitzis H, Laurent C, Vincent-Salomon A, Cottu P, Lerebours F, Rouzier R, Lae M, Reyal F (2017) Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer. Ann Oncol 28(9):2233–2240. https://doi.org/10.1093/annonc/mdx309

    Article  PubMed  Google Scholar 

  36. Force J, Howie LJ, Abbott SE, Bentley R, Marcom PK, Kimmick G, Westbrook K, Sammons SL, Parks M, Topping DL, Emerson R, Broadwater G, Hyslop T, Blackwell KL, Nair SK (2018) Early stage HER2-positive breast cancers not achieving a pCR from neoadjuvant trastuzumab- or pertuzumab-based regimens have an immunosuppressive phenotype. Clin Breast Cancer 18(5):410–417. https://doi.org/10.1016/j.clbc.2018.02.010

    Article  CAS  PubMed  Google Scholar 

  37. Luen SJ, Salgado R, Fox S, Savas P, Eng-Wong J, Clark E, Kiermaier A, Swain SM, Baselga J, Michiels S, Loi S (2017) Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. Lancet Oncol 18(1):52–62. https://doi.org/10.1016/S1470-2045(16)30631-3

    Article  CAS  PubMed  Google Scholar 

  38. Hou Y, Nitta H, Wei L, Banks PM, Lustberg M, Wesolowski R, Ramaswamy B, Parwani AV, Li Z (2018) PD-L1 expression and CD8-positive T cells are associated with favorable survival in HER2-positive invasive breast cancer. Breast J 24(6):911–919. https://doi.org/10.1111/tbj.13112

    Article  CAS  PubMed  Google Scholar 

  39. Zhao J, Meisel J, Guo Y, Nahta R, Hsieh KL, Peng L, Wei Z, O’Regan R, Li X (2020) Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies. Breast Cancer Res Treat 183(3):599–606. https://doi.org/10.1007/s10549-020-05819-8

    Article  CAS  PubMed  Google Scholar 

  40. De Angelis C, Nagi C, Hoyt CC, Liu L, Roman K, Wang C, Zheng Y, Veeraraghavan J, Sethunath V, Nuciforo P, Wang T, Tsimelzon A, Mao S, Hilsenbeck SG, Trivedi MV, Cataldo ML, Pavlick A, Wolff AC, Weigelt B, Reis-Filho JS, Prat A, Gutierrez C, Osborne CK, Rimawi MF, Schiff R (2020) Evaluation of the predictive role of tumor immune infiltrate in patients with HER2-positive breast cancer treated with neoadjuvant anti-HER2 therapy without chemotherapy. Clin Cancer Res 26(3):738–745. https://doi.org/10.1158/1078-0432.CCR-19-1402

    Article  PubMed  Google Scholar 

  41. Szekely B, Bossuyt V, Li X, Wali VB, Patwardhan GA, Frederick C, Silber A, Park T, Harigopal M, Pelekanou V, Zhang M, Yan Q, Rimm DL, Bianchini G, Hatzis C, Pusztai L (2018) Immunological differences between primary and metastatic breast cancer. Ann Oncol 29(11):2232–2239. https://doi.org/10.1093/annonc/mdy399

    Article  CAS  PubMed  Google Scholar 

  42. Takada K, Kashiwagi S, Goto W, Asano Y, Takahashi K, Takashima T, Tomita S, Ohsawa M, Hirakawa K, Ohira M (2018) Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer. J Transl Med 16(1):86. https://doi.org/10.1186/s12967-018-1460-4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Honkanen TJ, Tikkanen A, Karihtala P, Makinen M, Vayrynen JP, Koivunen JP (2019) Prognostic and predictive role of tumour-associated macrophages in HER2 positive breast cancer. Sci Rep 9(1):10961. https://doi.org/10.1038/s41598-019-47375-2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Tiainen S, Tumelius R, Rilla K, Hamalainen K, Tammi M, Tammi R, Kosma VM, Oikari S, Auvinen P (2015) High numbers of macrophages, especially M2-like (CD163-positive), correlate with hyaluronan accumulation and poor outcome in breast cancer. Histopathology 66(6):873–883. https://doi.org/10.1111/his.12607

    Article  PubMed  Google Scholar 

  45. Verma C, Kaewkangsadan V, Eremin JM, Cowley GP, Ilyas M, El-Sheemy MA, Eremin O (2015) Natural killer (NK) cell profiles in blood and tumour in women with large and locally advanced breast cancer (LLABC) and their contribution to a pathological complete response (PCR) in the tumour following neoadjuvant chemotherapy (NAC): differential restoration of blood profiles by NAC and surgery. J Transl Med 13:180. https://doi.org/10.1186/s12967-015-0535-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Barroso-Sousa R, Barry WT, Guo H, Dillon D, Tan YB, Fuhrman K, Osmani W, Getz A, Baltay M, Dang C, Yardley D, Moy B, Marcom PK, Mittendorf EA, Krop IE, Winer EP, Tolaney SM (2019) The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial. Ann Oncol 30(4):575–581. https://doi.org/10.1093/annonc/mdz047

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Li R, Sant S, Brown E, Caramia F, Byrne A, Clarke K, Neeson M, J. NP, Darcy PK, Peterson S, Loi S (2020) PS10-04. Tucatinib favourably modulates the immune microenvironment and synergises with anti-PD1 therapy in a trastuzumab resistant HER2+ murine model [abstract] 2020 San Antonio Breast Cancer Symposium. https://www.abstractsonline.com/pp8/#!/9223/presentation/1337

  48. Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G, Campone M, Biganzoli L, Bonnefoi H, Jerusalem G, Bartsch R, Rabaglio-Poretti M, Kammler R, Maibach R, Smyth MJ, Di Leo A, Colleoni M, Viale G, Regan MM, Andre F, International Breast Cancer Study G, the Breast International G (2019) Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial. Lancet Oncol 20(3):371–382. https://doi.org/10.1016/S1470-2045(18)30812-X

    Article  Google Scholar 

  49. Chia S, Bedard PL, Hilton J, Amir E, Gelmon K, Goodwin R, Villa D, Cabanero M, Tu D, Tsao M, Seymour L (2019) A phase Ib trial of durvalumab in combination with trastuzumab in HER2-positive metastatic breast cancer (CCTG IND.229). Oncologist 24(11):1439–1445. https://doi.org/10.1634/theoncologist.2019-0321

  50. Emens LA, Esteva FJ, Beresford M, Saura C, De Laurentiis M, Kim SB, Im SA, Wang Y, Salgado R, Mani A, Shah J, Lambertini C, Liu H, de Haas SL, Patre M, Loi S (2020) Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol 21(10):1283–1295. https://doi.org/10.1016/S1470-2045(20)30465-4

    Article  CAS  PubMed  Google Scholar 

  51. Huober J, Barrios CH, Niikura N, Jarzab M, Chang Y-C, Huggins-Puhalla SL, Graupner V, Eiger D, Henschel V, Gochitashvili N, Lambertini C, Restuccia E, Zhang H (2021) VP6-2021: IMpassion050: a phase III study of neoadjuvant atezolizumab + pertuzumab +trastuzumab + chemotherapy (neoadj A + PH + CT) in high-risk, HER2-positive early breast cancer (EBC). In: ESMO congress, virtual. https://doi.org/10.1016/j.annonc.2021.05.800

  52. Kuemmel S, Gluz O, Reinisch M et al (2022) KEYRICHED-1—a prospective, multicenter, open label, neoadjuvant phase II single arm study with pembrolizumab in combination with dual anti-HER2 blockade with trastuzumab and pertuzumab in early breast cancer patients with molecular HER2-enriched intrinsic subtype. Presented at: 2021 SABCS; December 7–10, 2021. Poster P2-13-03

  53. Hamilton E, Shapiro CL, Petrylak D, Boni V, Martin M, Del Conte G, Cortes J, Agarwal L, Arkenau HT, Tan AR, Debruyne P, Minchom A, Rutten A, Valdes-Albini F, Yu EY, Augustine B, D'Amelio J, Barrios D, Hurvitz SA (2020) Trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: a 2-part, phase 1b, multicenter, open-label study [abstract]. Presented at the 2020 San Antonio breast cancer symposium. https://www.abstractsonline.com/pp8/#!/9223/presentation/798

  54. Rugo HS, Im SA, Cardoso F, Cortes J, Curigliano G, Musolino A, Pegram MD, Wright GS, Saura C, Escriva-de-Romani S, De Laurentiis M, Levy C, Brown-Glaberman U, Ferrero JM, de Boer M, Kim SB, Petrakova K, Yardley DA, Freedman O, Jakobsen EH, Kaufman B, Yerushalmi R, Fasching PA, Nordstrom JL, Bonvini E, Koenig S, Edlich S, Hong S, Rock EP, Gradishar WJ, Group SS (2021) Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2020.7932

    Article  Google Scholar 

  55. Rugo HS, Im SA, Cardoso F, Cortes J, Curigliano G, Musolino A, Pegram MD, Bachelot T, Wright G, Saura C, Escrivá-de-Romaní S, De Laurentiis M, Schwartz GN, Pluard T, Ricci F, Gwin W III, Levy C, Brown-Glaberman U, Ferrero J-M, de Boer M, Kim S-B, Petráková K, Yardley DA, Freedman O, Jakobsen EH, Gal-Yam EN, Yerushalmi R, Fasching PA, Ashley E, Hong S, Rosales M and Gradishar WJ (2021 PD8–-01. Phase 3 SOPHIA study of margetuximab (M) + chemotherapy (CTX) vs trastuzumab (T) + CTX in patients (pts) with HER2+ metastatic breast cancer (MBC) after prior anti-HER2 therapies: final overall survival (OS) analysis. In: San Antonio breast cancer symposium, San Antonio, TX

  56. Meric-Bernstam F, Beeram M, Ignacio Mayordomo J, Hanna DL, Ajani J, Blum Murphy MA, Murthy RK, Piha-Paul SA, Bauer TM, Bendell J, El-Khoueiry AB, Lenz HJ, Press MF, Royer N, Hausman DF, Hamilton EP (2018) Single agent activity of ZW25, a HER2‑targeted bispecific antibody, in heavily pretreated HER2‑expressing cancers [abstract]. J Clin Oncol 36(suppl; abstr 2500):abstr 2500

  57. Bedard PL, Im SA, Elimova e, Rha SY, Goodwin R, Ferrario C, Lee K-W, Hanna D, Meric-Bernstam F, Mayordomo J, Beeram M, Hamilton E, Chaves J, Cobleigh M, Mwatha T, Woolery J, Oh DY (2021) P2-13-07. Zanidatamab (ZW25), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) for HER2-positive breast cancer (BC): results from a phase 1 study. In: San Antonio breast cancer symposium, San Antonio, TX

  58. Wermke M, Alt J, Kauh JS, Back J, Salhi Y, Reddy V, Bayever E, Ochsenreither S (2018) Preliminary biomarker and pharmacodynamic data from a phase I study of single-agent bispecific antibody T-cell engager GBR 1302 in subjects with HER2-positive cancers [abstract]. J Clin Oncol 36(5 (suppl)):69

  59. Hinner MJ, Bel Aiba R, Wiedenmann A, Schlosser C, Allersdorfer A, Matschiner G, Rothe C, Moebius U, Kohrt HE, Olwill SA (2015) Costimulatory T cell engagement via a novel bispecific anti-CD137 /anti-HER2 protein [abstract]. J Immunother Cancer 3(Suppl 2):P187

    Article  PubMed Central  Google Scholar 

  60. Pallerla S, Abdul A, Comeau J, Jois S (2021) Cancer vaccines, treatment of the future: with emphasis on HER2-positive breast cancer. Int J Mol Sci. https://doi.org/10.3390/ijms22020779

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank Kaitlyn T. Bifolck, BA, for her editorial support.

Funding

This manuscript did not receive specific funding.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Catalan Institute of Oncology - ICO, L’Hospitalet de Llobregat, Barcelona, Spain

    Sonia Pernas

  2. Breast Cancer Group, Institut d’Investigacio Biomedica de Bellvitge - IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain

    Sonia Pernas

  3. Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA

    Sara M. Tolaney

  4. Harvard Medical School, Boston, MA, USA

    Sara M. Tolaney

Authors
  1. Sonia Pernas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sara M. Tolaney
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SP performed the literature search and drafted the manuscript, and ST critically revised the work.

Corresponding author

Correspondence to Sara M. Tolaney.

Ethics declarations

Conflict of interest

SP reports advisor/consultant role for AstraZeneca, Daiichi-Sankyo, Polyphor, Novartis, Eisai, Pierre-Fabre, SeattleGenetics, and Roche. SMT reports institutional research funding from AstraZeneca, Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics, Exelixis, Bristol-Myers Squibb, Eisai, Nanostring, Cyclacel, Odonate, Seattle Genetics; and advisor/consultant role for AstraZeneca, Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Gilead, Immunomedics, Bristol-Myers Squibb, Eisai, Nanostring, Puma, Sanofi, Celldex, Paxman, Odonate, Seattle Genetics, Silverback Therapeutics, G1 Therapeutics, AbbVie, Anthenex, OncoPep, Outcomes4Me, Kyowa Kirin Pharmaceuticals, Daiichi-Sankyo, Samsung Bioepsis Inc.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Informed consent

Not applicable.

Research involving human and/or animals participants

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pernas, S., Tolaney, S.M. Clinical trial data and emerging strategies: HER2-positive breast cancer. Breast Cancer Res Treat 193, 281–291 (2022). https://doi.org/10.1007/s10549-022-06575-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-022-06575-7

Keywords

Search

Navigation